Fingerprint
Dive into the research topics of 'A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically